http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2548754-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a828cdddb3eab8b856b92ea68ccbfc6e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2014-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9a2ce7e93e65dd631a7081aa8fb7b53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a808f9d34a266367bb0c5b6bfaae094b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04a64536f4283bb8191350bfe0a3f6f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1923925118b78cbfc148b44489eeff30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa5ae0464f3d4fbdadf147f137155dcb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fc0827e27204266c5fd6619e887f284 |
| publicationDate | 2015-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2548754-C1 |
| titleOfInvention | Method for predicting cytoprotective effect of immunoglobulins for intravenous administration in therapy of females with recurrent pregnancy loss and diagnosed anti-phospholipid syndrome |
| abstract | FIELD: medicine. n SUBSTANCE: portion of endothelial cell culture is pre-processed with immunoglobulins for intravenous administration, while the other portion is left unprocessed, cultured with female's blood serum to measure a percentage of non-viable endothelial cells processed with immunoglobulins for intravenous administration. A percentage of non-viable endothelial cells unprocessed with immunoglobulins for intravenous administration is also determined. The cytoprotective effect is calculated in per cent by formula: CE=100-100X/X1, wherein X is the percentage of non-viable endothelial cells processed with immunoglobulins after culturing with blood serum; X1 is the percentage of non-viable endothelial cells unprocessed with immunoglobulins after culturing with blood serum. If the derived value is more than 55%, the cytoprotective effect is considered to be positive. n EFFECT: method enables predicting the cytoprotective effect of intravenous immunoglobulins both in treating the females suffering recurrent pregnancy loss and diagnosed anti-phospholipid syndrome, and in treating some other diseases related to endothelial injuries and derived endothelial dysfunction. n 6 dwg, 3 tbl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2768461-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2775311-C1 |
| priorityDate | 2014-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.